Ain Holdings Inc.
【Ain Holdings】Revision of Full-Year Business Performance Forecast and Dividend Increase｜May 2026
Ain Holdings revised upward its full-year consolidated earnings forecast for the fiscal year ending April 2026, projecting net income of 17,000 million JPY. The year-end dividend has also been increased to 100 yen, strengthening shareholder returns.
Key Figures
- Sales: 647,500 million JPY (compared to previous forecast +1,500 million JPY)
- Net income attributable to owners of parent: 17,000 million JPY (compared to previous forecast +3,500 million JPY)
- Year-end dividend: 100.00 yen (increase of 20.00 yen)
AI要約
Performance Overview
Ain Holdings has upwardly revised its consolidated earnings forecast for the fiscal year ending April 2026, expecting sales of 647,500 million JPY, an increase of 0.2% from the previous forecast, and net income of 17,000 million JPY, a 25.9% increase. Revenue improvements are driven by higher prescription unit prices for high-priced pharmaceuticals and progress in PMI for the Sakura Drugstore Group. Consequently, the year-end dividend for the fiscal year ending April 2026 has been increased to 100 yen, reinforcing shareholder returns.
Impact on Shareholders and Future Outlook
This revision of performance and dividend increase further strengthens the company's shareholder return policy. Going forward, the company aims to expand its pharmaceutical business and improve profitability, pursuing stable growth. From an investor's perspective, the company is expected to become an attractive investment destination due to both improved earnings and increased dividends.
Ain Holdings
Company overview · Stock price · Financial data · All IR
